2008/04/14 12:56 - Ventracor Limited (ASX:VCR)(US:VTCRY) today released the clinical results of the US Feasibility Trial of the VentrAssist(R) Left Ventricular Assist Device (LVAD). The results were presented on Saturday 12 April at the annual meeting of the International Society of Heart and Lung Transplantation (ISHLT) in Boston by Dr. Andrew Boyle, Assistant Professor of Medicine at the University of Minnesota Medical School, in Minneapolis MN.
2008/04/03 13:55 - Ventracor Limited (ASX: VCR)(PNK: VTCRY) CEO, Peter Crosby Letter to Shareholders
2008/04/03 12:35 - Leading Australian developer and manufacturer of prosthetic implants and medical devices, Advanced Surgical Design and Manufacture Limited (ASX: AMT) announces that this Thursday's episode of Catalyst (ABC TV) will feature the Limb Saving clinical trial currently being undertaken by AllVascular Pty Ltd and utilising the PAD access device developed with Advanced Surgical and exclusively manufactured by Advanced Surgical.
2008/04/03 10:51 - Ventracor Limited (ASX: VCR)(PNK: VTCRY) announced today changes to the Board of Directors. John Massey has retired as a Director and Chairman of the Board. John Ward has been elected Chairman of the Board of Directors, and William Curran takes on the role of Chairman of the Audit, Risk and Compliance Committee.
2008/03/17 09:52 - Ventracor Limited (ASX: VCR)(ADR: VTCRY) announced today that the US Food and Drug Administration (FDA) has granted unconditional approval for the US Destination Therapy Trial of the VentrAssist Left Ventricular Assist Device (LVAD).
2008/03/13 11:13 - Ventracor (ASX: VCR) announced today the appointment of Professor Mariell Jessup as Cardiology Principal Investigator of the US Destination Therapy Trial of the VentrAssist Left Ventricular Assist Device (LVAD).
2008/02/26 15:22 - Ellex Medical Lasers Limited (ASX:ELX), a global leader in the design and manufacture of ophthalmic laser and ultrasound systems, today announced its financial results for the half year ended 31 December 2007. The result demonstrated strong, continuous growth in the business with revenues growing 19% over the prior comparable period.
2008/02/18 19:53 - ASX listed company, Safety Medical Products Limited (ASX: SFP)(SafetyMed), announced today it had been granted approval by the Federal Department of Health to supply the first ever Australian made retractable syringes to the National Diabetes Services Scheme (NDSS).
2008/02/11 14:09 - Ventracor (ASX: VCR) has implanted the 200th patient with its VentrAssist(tm) Left Ventricular Assist Device (LVAD)
2008/01/21 13:35 - Eastland Medical Systems Ltd (ASX: EMS) remains on track with the development of its anti-malaria treatment ArTiMistTM and will commence a multi dose Phase 1 clinical trial for ArTiMistTM in February, after its Pharmaceutical Division receiving approval from the South African MCC Regulatory Body.
2008/01/15 13:19 - Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) wishes to advise of its progress in licensing its core intellectual property pertaining to non-coding DNA.
2007/12/21 12:27 - Occupational & Medical Innovations Limited (ASX: OMI) today announced the receipt of its opening US sales order from its leading North American distributor for the auto retractable safety syringe.
2007/12/19 11:54 - Eastland Medical Systems (ASX EMS) is looking to significantly increase revenues in 2008 as a result of its decision to concentrate on the development of its Pharmaceutical Division - with fast-track low-risk pharmaceutical development and early market entry of pharmaceutical product.
2007/12/19 09:42 - Ventracor (ASX: VCR) today announced CE Marking approval for the next version of the VentrAssist(tm) left ventricular assist device (LVAD) which allows it to be marketed and sold in Europe.
2007/12/18 14:04 - Ventracor (ASX: VCR) today announced US Food & Drug Administration (FDA) approval to use the new version of its VentrAssist(tm) left ventricular assist device (LVAD) in its US clinical trial program.
2007/12/17 12:43 - Phosphagenics Limited ("Phosphagenics") (ASX: POH)(AIM: PSG)(OTCQX: PPGNY) today announced positive results of its Phase 1 clinical trial that showed its delivery technology, TPM, delivered leading pain-relief drug oxycodone through the skin without causing any disruption or irritation.
2007/12/03 09:14 - Ventracor (ASX: VCR) today welcomed a major milestone in the growth of the worldwide industry for Left Ventricular Assist Devices (LVADs).
2007/11/22 10:18 - The Annual General Meeting of Ventracor Limited was held in Brisbane on 24 October and was well attended. We were very grateful and pleased to see the continuing interest and support by our shareholders. All resolutions put to the meeting were passed.
2007/11/20 13:32 - Ventracor (ASX: VCR) today announced 10 US hospitals have implanted at least one VentrAssist(tm) as part of its US clinical trials, and that more centres are trained and awaiting availability of patients.
2007/10/29 11:54 - Signing of an exclusive agreement with one of the world's largest pharmaceutical groups in December 2006 to develop the UnitractTM Prefilled Syringe for one of its major drug products. After a successful review of product specifications in July 2007, both parties are now finalizing an extension of this agreement.
2007/10/08 19:03 - Unilife Medical Solutions Limited ("Unilife") (ASX: UNI) is pleased to announce the successful testing of its fully automated assembly line developed for the manufacture of the Unitract(tm) range of 1mL syringes at its US facility, Integrated BioSciences Inc ("IBS")
2007/10/05 16:01 - Ventracor (ASX: VCR) today announced the 150th implant of the VentrAssist Left Ventricular Assist Device (LVAD).
2007/08/16 21:40 - Ventracor (ASX: VCR) today announced its results for the year ending 30 June 2007, with increasing sales revenues in the US, Europe and Australasia of $4.9m (2006;$1.1m) from 64 implants, and a net loss of $36.5m (2006;$30m).
2007/07/13 13:46 - Following significant shareholder enquiry, the Company provides an update of the status of the international clinical trial currently underway for HeartWare's (ASX: HTW) HVAD TM Left Ventricular Assist Device.
2007/06/26 09:50 - Ellex Medical Lasers Limited (ASX: ELX) - Raises $5.5 million through Placement - Mr Peter Falzon, CEO; Boardroomradio is pleased to announce that Ellex Medical Lasers Limited (ASX: ELX) has published an audio file.
2007/06/06 10:32 - Ventracor (ASX: VCR)(ADR: VTCRY) today announced the first patient implant in the US Bridge to Transplant (BTT) pivotal trial of the VentrAssist(tm) left ventricular assist device (LVAD) at the Medical University of Minnesota, in Minneapolis.
2007/06/05 12:47 - Ventracor (ASX: VCR)(ADR: VTCRY) yesterday confirmed growing momentum in Europe and the USA, with increases in the number of VentrAssist(tm) Left Ventricular Assist Device (LVAD) implants, resulting in record monthly sales revenue.
2007/05/29 21:28 - Ventracor (ASX: VCR) (ADR: VTCRY) is about to commence two major clinical trials in the US after the company successfully completed a Feasibility Trial. The first is a Bridge to Transplant (BTT) Pivotal Trial for patients on the transplant list; the FDA recently approved the start of this trial.
2007/05/02 15:15 - Mr William Curran, who joins the board effective immediately, is a New York-based company director with extensive experience in the medical device industry, including a 28-year career with Philips culminating in a senior role with Philips Medical Systems in USA.
2007/03/29 10:54 - We are pleased and proud that the VentrAssist is an Australian success story that has improved the lives of almost 100 patients world-wide. The VentrAssist is still the only centrifugal LVAD and the only third generation LVAD in clinical trials in the USA. There is more world-wide clinical experience with the VentrAssist than all centrifugal LVADs from all competitors, combined.
2007/03/19 13:23 - Safety Medical Products Ltd is pleased to announce the successful commencement of commissioning of the Securetouch Retractable Syringe Assembly Machine.
2006/11/24 09:10 - Premier Bionics (ASX: PBI)(AIM: PBI), the Australian-based company that was formed to invest in medical devices and diagnostics, today announces through its solely owned subsidiary company, Medic Vision Pty Ltd, the signing of a contract between the University of Liverpool, Royal Liverpool University, Broadgreen Hospitals NHS Trust, Imperial College London, University of Wales (Bangor), University of Hull, University of Leeds, Central Manchester & Manchester Children's University Hospitals NHS Trust and Medic Vision to develop a visceral needle puncture simulator for commercial deployment.
2006/08/15 14:42 - The August 2006 edition of our Health & Life Science Quarterly Blue Book profiles niche life sciences companies, with a focus on company strategies, key projects and significant milestones.
2006/07/14 13:49 - AOS - TetraFlex Update - Significant Commercial Progress Achieved; Prof. Simon Carroll, Chief Scientific Officer) is available as an Audio file. The following presentation "TetraFlex Update - Significant Commercial Progress Achieved" is now available as an instant audio download to your computer.
2006/06/16 16:21 - Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) is pleased to announce that it has entered into an agreement with DNA Bioservices Pty. Ltd. to provide paternity testing services to China.
2006/06/15 14:42 - With reference to the clinical trial currently underway for HeartWare's (ASX: HTW) HVAD left ventricular assist device, Mr McConchie commented:
2006/05/23 10:03 - HeartWare (ASX: HTW) in accordance with ASX Listing Rule 3.13.3 provides a copy of the presentations which are to be delivered today at the Company's Annual General Meeting.
2006/05/22 11:18 - HeartWare (ASX: HTW) is pleased to announce that it has received regulatory approval from the Medicines and Healthcare Products Regulatory Agency ("MHRA") to commence implants of its HVAD circulatory assist device in the United Kingdom.
2006/05/19 13:04 - HeartWare Limited (ASX: HTW) announced to shareholders the Share Purchase Plan dated 19 May 2006 (Plan). The Plan allows shareholders to purchase up to A$5,000 worth of ordinary shares in HeartWare Limited (Heartware or the Company) at A$1.10 per share, which is an issue price discounted to the market price of HeartWare shares on the Australian Stock Exchange (ASX) and free of brokerage or transaction costs.
2006/05/10 16:08 - HeartWare Limited (ASX: HTW) is pleased to announce that it has received commitments for $32.5 million from institutional and sophisticated investors in Australia and the United States.
Biotech